Big effect
A probiotic slashed eczema risk by 60% in high-risk infants — but the finding comes from a single trial in a very specific population.
This is a striking result, but it's early evidence; the body of research on this specific probiotic and eczema is thin, and the effect may not generalize beyond the high-risk infant group studied.
In a double-blind trial, 5 billion CFU daily of Bifidobacterium lactis BLa80 given to high-risk infants reduced eczema incidence from 69.5% to 27.6% over 180 days. The probiotic also appeared to lower respiratory infections and improve gut health markers. However, because the study only involved infants at high risk for allergies, the results may not apply to older children or adults, and more research is needed to confirm the findings.
Where this fits in the evidence
This is among the first studies we've indexed on Bifidobacterium lactis BLA80 for Reduced Eczema Incidence — treat it as an early signal until more research accumulates.
The study
- Clinical Trial
- 2026-05-28
- Frontiers in nutrition
This is a plain-language summary of a research finding, not medical advice. Pillser surfaces research signals to help you decide what's worth investigating — always consult a qualified professional before changing what you take.